Nonbacterial thrombotic endocarditis of a bioprosthetic valve: Questions to ponder before replacement of the valve

Nonbacterial thrombotic endocarditis (NBTE) of bioprosthetic valves is extremely rare. We report a 67-year-old lady with early bioprosthetic “failure” that at reoperation was proven to be NBTE. The choice of a prosthesis in this condition may have implications for patients’ late clinical course.     

Valve-on-valve technique for replacement of degenerated tricuspid bioprosthetic valve without explantation

A 73-year-old woman admitted to our hospital with shortness of breath and edema of the lower extremities was diagnosed with right ventricular failure stemming from tricuspid valve regurgitation. She had undergone mitral valve replacement (MVR) with a mechanical valve at the age of 51, and reoperative MVR with mechanical valve, tricuspid valve replacement (TVR) with bioprosthetic valve, and pacemaker implantation at the age of 63. Reoperative TVR was performed when the patient failed to respond to drug therapy. A beating heart cardiopulmonary bypass procedure was performed in which only the bioprosthetic valve leaflet was excised, and reoperative TVR was performed with a 27-mm OptiForm^TM mechanical mitral valve (Sulzer Carbomedics Inc., Austin, TX, USA) by the valve-on-valve technique. The operative course was uneventful. The technique used here appears to be an effective approach to reoperative TVR, in this instance making it possible to avoid the risks associated with excision of the old prosthesis.     

Persistent cardiac failure after mitral valve replacement due to free-floating intracardiac thrombus formation

A case of free-floating left atrial-ventricular thrombus early after mitral valve replacement (Carpentier-Edwards pericardial bioprosthesis) is presented. Successful surgical removal was performed. The diagnostic and therapeutic efforts are discussed.     

Early bioprosthetic tricuspid valve stenosis due to size mismatch in Ebstein anomaly—Successful transcatheter treatment

Patients with congenital heart disease are surviving well into adulthood thanks to advances in medical and clinical care. We present a patient with Ebstein anomaly who underwent surgical tricuspid valve replacement and suffered early valve stenosis due to her unique anatomy. This case highlights the importance of the “unnatural” anatomy that can be encounter in this challenging patient population.     

Does antiphospholipid antibody syndrome affect bioprosthetic heart valve?

Cardiovascular involvements in antiphospholipid antibody syndrome have been recognized as a major complication of this disease. Furthermore, some papers report bioprosthetic heart valve also seems to be affected. A 32-year-old female with aortic regurgitation presented to our hospital. Further examination revealed high titer of anticardiolipin beta 2 glycoprotein 1 antibody, and she was diagnosed as having primary antiphospholipid antibody syndrome since the patient failed to match the criteria of systemic lupus erythematosus. Cardiopulmonary bypass was uneventfully conducted under systemic heparinization of usual dosage. Administration of warfarin sodium was started on the third postoperative day, and international normalized ratio was controlled from 2.0 to 2.5. On echocardiographic examination at 1 month, mean systolic gradient was 17 mmHg. Although transesophageal echocardiography at 2 years after surgery revealed no sign of valvular destruction or sclerosis, transaortic gradient had increased to 26 mmHg. Bioprosthetic stenosis was suspected probably due to pannus formation and the patient may have to undergo another valve replacement in the near future.     

Does antiphospholipid antibody syndrome affect bioprosthetic heart valve?

Cardiovascular involvements in antiphospholipid antibody syndrome have been recognized as a major complication of this disease. Furthermore, some papers report bioprosthetic heart valve also seems to be affected. A 32-year-old female with aortic regurgitation presented to our hospital. Further examination revealed high titer of anticardiolipin beta 2 glycoprotein 1 antibody, and she was diagnosed as having primary antiphospholipid antibody syndrome since the patient failed to match the criteria of systemic lupus erythematosus. Cardiopulmonary bypass was uneventfully conducted under systemic heparinization of usual dosage. Administration of warfarin sodium was started on the third postoperative day, and international normalized ratio was controlled from 2.0 to 2.5. On echocardiographic examination at 1 month, mean systolic gradient was 17 mmHg. Although transesophageal echocardiography at 2 years after surgery revealed no sign of valvular destruction or sclerosis, transaortic gradient had increased to 26 mmHg. Bioprosthetic stenosis was suspected probably due to pannus formation and the patient may have to undergo another valve replacement in the near future.     

Late results of mitral valve repair for mitral regurgitation

OBJECTIVE: This study was undertaken to evaluate the long-term results of mitral valve repair for mitral regurgitation. METHODS: Between 1991 and 2000, 301 patients with mitral regurgitation underwent mitral valve repair. There were 167 men and 134 women whose mean age was 56 +/- 14 years. The patients were comprised of 7 patients in Carpentier's type I, 277 patients in type II, and 17 patients in type III. Chordal replacement with expanded polytetrafluoroethylene sutures had been prospectively applied to repair the anterior mitral leaflet prolapse. Ring annuloplasty was performed in 230 patients (76%). The follow-up was complete and mean follow-up was 67 +/- 33 months, for a cumulative follow-up of 1,624 patient-years. RESULTS: There were 5 hospital deaths and 11 late deaths (2 cardiac and 9 noncardiac). All survivors except those with stroke were in the New York Heart Association (NYHA) functional class I or II. At 10 years, the actuarial survival was 90 +/- 3%, the freedom from embolism was 86 +/- 4%, the freedom from reoperation was 96 +/- 2%, and the freedom from valve-related events was 77 +/- 4%. At 10 years, the freedom from reoperation in the patients with anterior leaflet prolapse was 90 +/- 5%. CONCLUSIONS: Mitral valve repair is feasible in most patients with mitral regurgitation and is associated with low mortality and low rates of valve related events. Chordal replacement with expanded polytetrafluoroethylene sutures is effective, safe, and durable at long-term follow-up for patients with anterior leaflet prolapse.     

Late results of mitral valve repair for mitral regurgitation

Objective: This study was undertaken to evaluate the long-term results of mitral valve repair for mitral regurgitation.Methods: Between 1991 and 2000, 301 patients with mitral regurgitation underwent mitral valve repair. There were 167 men and 134 women whose mean age was 56±14 years. The patients were comprised of 7 patients in Carpentier's type I, 277 patients in type II, and 17 patients in type III. Chordal replacement with expanded polytetrafluoroethylene sutures had been prospectively applied to repair the anterior mitral leaflet prolapse. Ring annuloplasty was performed in 230 patients (76%). The follow-up was complete and mean follow-up was 67±33 months, for a cumulative follow-up of 1,624 patient-years.Results: There were 5 hospital deaths and 11 late deaths (2 cardiac and 9 noncardiac). All survivors except those with stroke were in the New York Heart Association (NYHA) functional class I or II. At 10 years, the actuarial survival was 90±3%, the freedom from embolism was 86±4%, the freedom from reoperation was 96±2%, and the freedom from valve-related events was 77±4%. At 10 years, the freedom from reoperation in the patients with anterior leaflet prolapse was 90±5%.Conclusions: Mitral valve repair is feasible in most patients with mitral regurgitation and is associated with low mortality and low rates of valve related events. Chordal replacement with expanded polytetrafluoroethylene sutures is effective, safe, and durable at long-term follow-up for patients with anterior leaflet prolapse. Read at the Fifty-fifth Annual Meeting of The Japanese Association for Thoracic Surgery, Symposium, Fukuoka, October 9–11, 2002.     

Papillary fibroelastoma of the mitral valve associated with rheumatic mitral valve stenosis

With the advent of echocardiography, diagnosis of papillary fibroelastoma in living patients has been made possible, yet papillary fibroelastoma found in the living remains a very rare cardiac tumor. We report a case of papillary fibroelastoma of the mitral valve with rheumatic mitral valve stenosis. A 68-year-old woman was referred to our hospital with a mitral valve tumor and rheumatic mitral valve stenosis. She underwent anticoagulation therapy with Warfarin for 8 years since having a cerebral embolization. Echocardiography revealed a mass attached to the mitral valve, with severe mitral valve stenosis. Electrocardiography demonstrated a chronic atrial fibrillation. Tumor excision with mitral valve replacement and maze procedure were performed. Both the surgical and histological findings depicted papillary fibroelastoma. The postoperative course was uneventful and the patient has remained symptom-free one year after surgery.     

Left ventricular rupture following mitral valve replacement due to oversize prosthesis

Left ventricular rupture following mitral valve replacement is one of the most serious complications. We report our experience in successful treatment of type III left ventricular rupture following mitral valve replacement probably due to an oversize prosthesis. A 67-year-old woman, with the history of percutaneous transluminal mitral commissurotomy 11 years previously, underwent mitral valve replacement for mitral restenosis with a 27 mm CarboMedics mechanical bileaflet valve (Sulzer CarboMedics Inc., Austin, TX, U.S.A.). There were some difficulties in placing the entire prosthesis into the annulus at the posterior because of the oversize prosthesis. After the complete placement of the prosthesis, bulge of the left ventricular muscle was evident around the left lateral region. Following the cessation of cardio-pulmonary bypass, type III left ventricular rupture, half a circular rip between the papillary muscles and posterior mitral annulus, occurred. The rip was suture-closed and a 23 mm CarboMedics valve was placed. Postoperative ultrasonic cardiography showed no prosthetic stenosis, periprosthetic leak, left ventricular pseudoaneurysm, nor left ventricular asynergy. Under cardioplegic arrest, we should not select the oversize prosthesis to prevent left ventricular rupture.     

Supravalvular mitral remnant: The other side of the… valve

We report a challenging clinical case of an atypical supravalvular mitral remnant in recent mitral and aortic valve replacement with mechanical valve prostheses, associated with postoperative recurrent inflammatory episodes overlapped with difficult anticoagulation. Negative myocardial scintigraphy was associated with persistence of negative blood cultures. Serial echocardiographic evaluation was performed before and after antimicrobial treatment, and at 3 months follow-up a transesophageal echocardiography showed the persistence of the mass. Diagnostic suspect was finally confirmed.     

Transcatheter mitral valve therapies: State of the art

Mitral regurgitation (MR) is one of the most prevalent valvular pathologies in the developed world. There continues to be a growing population of aging patients with MR who may be too high risk for surgical management. The rapid adoption and remarkable success of transcatheter aortic valve replacement (TAVR) generated enthusiasm for transcatheter mitral valve therapies; however, the complex anatomy and pathophysiology of the mitral valve confers several unique challenges for a fully percutaneous approach. Nevertheless, several devices are under development and in various phases of preclinical or clinical testing, both for transcatheter mitral valve replacement and repair. MitraClip (Abbott Vascular), which has received FDA approval, is the most established percutaneous repair strategy and has been performed in over 80,000 patients as of 2019. The following article serves as a review of the available and upcoming devices for the various etiologies of mitral valvular disease, as well as the unique challenges and potential complications of transcatheter mitral valve intervention.     

Implantation of collar-reinforced SuMit valve for patient with large calcified mass obstructing the mitral valve orifice

A 56-year-old female had a severely calcified mitral valve annulus and a huge subvalvular mass. To avoid critical damages of the coronary artery and left ventricle, the annular calcification and the part of the mass adherent to the left ventricle were not resected. Then we performed mitral valve replacement using SuMit^TM valve and collared reinforcement technique with xenopericardium without any major complications. The SuMit^TM valve is designed to be placed in a supraannular position, and is useful to prevent valves from getting stuck.